IEQ Capital
IBRX icon

IEQ Capital’s ImmunityBio IBRX Stock Holding History

IEQ Capital’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$145K Buy
15,357
+257
+2% +$2.05K ﹤0.01% 1830
2026
Q2 		$132K Sell
15,100
-10,000
-40% -$75.7K ﹤0.01% 1901
2026
Q1 		$193K Buy
25,100
+15,100
+151% +$103K ﹤0.01% 1708
2025
Q4 		$19.8K Sell
10,000
-11,476
-53% -$26K ﹤0.01% 1827
2025
Q3 		$52.8K Sell
21,476
-8,305
-28% -$21.4K ﹤0.01% 1796
2025
Q2 		$78.6K Buy
+29,781
New +$80.1K ﹤0.01% 1740

Other funds holding IBRX

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

IEQ Capital's IBRX Position: Q3 2026 in Review

IEQ Capital increased its ImmunityBio (IBRX) stake by 1.7% in Q3 2026, buying an estimated $2.05K and bringing the position to 15,357 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #1830.

IEQ Capital first reported a position in IBRX in Q2 2025 and has held it in 6 quarters since. The position peaked at $193K in Q1 2026. 280 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • IEQ Capital held 15,357 shares of ImmunityBio worth $145K as of Q3 2026.
  • IEQ Capital bought 257 ImmunityBio shares in Q3 2026, an estimated $2.05K.
  • ImmunityBio made up ﹤0.01% of IEQ Capital's portfolio in Q3 2026, its #1830 holding.
  • IEQ Capital first reported a position in ImmunityBio in Q2 2025 and has held it in 6 quarters since.
  • IEQ Capital's ImmunityBio position peaked at $193K in Q1 2026.
  • 280 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on IEQ Capital's 13F filing for Q3 2026, filed 10 Nov 2026.